2024
Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Buckley S, Derkach A, Roman‐Torres K, Rampal R. Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival. European Journal Of Haematology 2024, 114: 238-247. PMID: 39400386, PMCID: PMC11707811, DOI: 10.1111/ejh.14321.Peer-Reviewed Original ResearchSpleen volume reductionOverall survivalOS benefitNon-respondersAssociated with improved OSPatients treated with ruxolitinibAssociated with overall survivalAssociated with significant OS benefitImproved overall survivalSignificant OS benefitPERSIST-2Analysis of survivalUnique survival advantagesInhibitor of Janus kinaseJanus kinaseOS curvesRetrospective analysisSurvival advantageMyelofibrosisPacritinibPatientsRuxolitinibPlateletThrombocytopeniaVolume reduction
2022
Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.
Reckamp K, Redman M, Dragnev K, Villaruz L, Faller B, Al Baghdadi T, Hines S, Qian L, Minichiello K, Gandara D, Kelly K, Herbst R. Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A. Journal Of Clinical Oncology 2022, 40: 9004-9004. DOI: 10.1200/jco.2022.40.16_suppl.9004.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced non-small cell lung cancerProgression-free survivalOverall survivalCell lung cancerProgressive diseaseLung cancerLung-MAPImmune checkpoint inhibitor therapyPlatinum-based doublet therapyRandomized phase II trialVEGF receptor inhibitionCheckpoint inhibitor therapyImproved overall survivalPD-L1 expressionPhase II trialPotential survival benefitDuration of responseLog-rank testStandard of careTumor mutational burdenMajor unmet needAnalysis of survivalMultiple tumor typesCare arm
2021
Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database
Cheng E, Blackburn HN, Ng K, Spiegelman D, Irwin ML, Ma X, Gross CP, Tabung FK, Giovannucci EL, Kunz PL, Llor X, Billingsley K, Meyerhardt JA, Ahuja N, Fuchs CS. Analysis of Survival Among Adults With Early-Onset Colorectal Cancer in the National Cancer Database. JAMA Network Open 2021, 4: e2112539. PMID: 34132794, PMCID: PMC8209612, DOI: 10.1001/jamanetworkopen.2021.12539.Peer-Reviewed Original ResearchConceptsEarly-onset colorectal cancerOnset colorectal cancerNational Cancer DatabaseColorectal cancerAge 51Overall survivalCancer DatabaseIncidence of CRCCox proportional hazards regressionPrimary colorectal cancerKaplan-Meier analysisProportional hazards regressionAge 50 yearsAge 25 yearsAnalysis of survivalCohort studySurvival benefitHazards regressionUnadjusted analysesCancer incidenceMAIN OUTCOMEAge 35Survival advantageLower riskStage INeoantigen driven B cell and CD4+ T follicular helper cell collaboration promotes robust anti-tumor CD8+ T cell responses
Cui C, Joshi N, Craft J. Neoantigen driven B cell and CD4+ T follicular helper cell collaboration promotes robust anti-tumor CD8+ T cell responses. The Journal Of Immunology 2021, 206: 57.01-57.01. DOI: 10.4049/jimmunol.206.supp.57.01.Peer-Reviewed Original ResearchT cell responsesAnti-tumor CD8Tfh cellsB cellsCell responsesIL-21Cell collaborationProtective anti-tumor responsesTfh-B cell interactionsTumor-specific B cellsGC B cell responsesTumor-specific CD4Anti-tumor immunityFavorable clinical outcomeAnti-tumor responseIL-21 receptorB cell responsesLung adenocarcinoma patientsAnalysis of survivalT cell-B cell interactionsGerminal center formationCell interactionsGC B cellsAbstract CD4Effector CD8
2018
Changing prognosis of oral cancer: An analysis of survival and treatment between 1973 and 2014
Cheraghlou S, Schettino A, Zogg CK, Judson BL. Changing prognosis of oral cancer: An analysis of survival and treatment between 1973 and 2014. The Laryngoscope 2018, 128: 2762-2769. PMID: 30194691, DOI: 10.1002/lary.27315.Peer-Reviewed Original ResearchConceptsOral cavity cancerLate-stage diseaseAdjuvant therapyOral cancerEnd Results 9 registriesCox survival regressionHigher nodal yieldsNational Cancer DatabaseEarly-stage diseaseKaplan-Meier analysisRetrospective database analysisAnalysis of survivalAdjuvant chemoradiotherapyNodal yieldAdult patientsNeck dissectionRetrospective studyCancer DatabasePrognosisPatientsCancerDiseaseDatabase analysisSurvival regressionChemoradiotherapy
2009
A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results?
Enestvedt C, Diggs B, Shipley D, Thomas C, Billingsley K. A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results? Gastrointestinal Cancer Research : GCR 2009, 3: 233-8. PMID: 21151426, PMCID: PMC3000069.Peer-Reviewed Original ResearchReceipt of chemoradiotherapyAdjuvant therapyAdjuvant chemoradiotherapyIndependent predictorsGastric adenocarcinomaGastric cancerResectable gastric adenocarcinomaModest survival benefitAmerican Joint CommitteeCurrent practice patternsState Cancer RegistryStandard of carePopulation-based analysisAnalysis of survivalGastric cancer treatmentChi-square testBinary logistic regressionEligible patientsN2 diseaseTreatment eraResection typeSurvival benefitLymph nodesAJCC stageCancer Registry
1999
Is Lymphadenectomy Necessary for Early Gastric Cancer?
Hochwald S, Brennan M, Klimstra D, Kim S, Karpeh M. Is Lymphadenectomy Necessary for Early Gastric Cancer? Annals Of Surgical Oncology 1999, 6: 664-670. PMID: 10560852, DOI: 10.1007/s10434-999-0664-5.Peer-Reviewed Original ResearchConceptsAssociated with decreased survivalNode-positive tumorsLymph node involvementPositive nodesMultivariate analysisNode involvementExcellent prognosisActuarial 5-year survivalCohort of Western patientsPredictors of nodal diseasePresence of positive nodesRate of positive nodesGastric cancerMedian follow-up timeUnivariate analysis of survivalDisease-specific survivalDied of diseaseProspective data baseAnalysis of survivalEarly gastric cancerEarly gastric carcinomaNodal diseaseT1 tumorsSurgical resectionLimited resection
1990
Tumor cell lines established in vitro: an independent prognostic factor for survival in non-small-cell lung cancer.
Stevenson H, Gazdar A, Phelps R, Linnoila R, Ihde D, Ghosh B, Walsh T, Woods E, Oie H, O'Connor T, Makuch R, Kramer B, Mulshine J. Tumor cell lines established in vitro: an independent prognostic factor for survival in non-small-cell lung cancer. Annals Of Internal Medicine 1990, 113: 764-70. PMID: 1700655, DOI: 10.7326/0003-4819-113-10-764.Peer-Reviewed Original ResearchConceptsNon-small-cell lung cancerTumor cell linesMedian survivalLung cancerRadiation therapyTumor specimensCell linesTumor tissuesMultivariate analysisTreated with radiation therapyTreated with surgical resectionIn vitro drug sensitivityUnivariate analysis of survivalCorrelated to clinical outcomeDecreased patient survivalLog-rank testIn vitro tumor growthIndicator of prognosisAnalysis of survivalStep-down techniqueSurgical resectionConsecutive patientsPrognostic factorsPalliative therapyBiological aggressiveness
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply